Search clinical trials for: Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

Total 511 results

University of California, San Diego
Gilead Sciences; University at Buffalo

Completed

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

HIV

United States
University of Hawaii
Gilead Sciences

Unknown

Sleep and Cognition After Atripla to Stribild Switch

HIV

United States
Johns Hopkins University
Gilead Sciences

Completed

Analysis of Crushed and Whole Tablet Genvoya

Healthy Volunteers

United States
Gilead Sciences

Completed

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States
Emory University
Centers for Disease Control and Prevention

Completed

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

HIV Infections

United States
Midtown Medical Center, Tampa, FL
Gilead Sciences

Completed

Atripla to Stribild Switch Study to Evaluate Sleep Disturbances

HIV | Sleep Disorders | AIDS
Vancouver Infectious Diseases Centre
Gilead Sciences; Regina General Hospital

Unknown

STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY) (SINNR)

HIV | Illicit Drug User

Canada
Radboud University Medical Center

Completed

Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet (CRUSTRI)

HIV

Netherlands
Emory University
Centers for Disease Control and Prevention

Completed

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

HIV/AIDS

United States
Massachusetts General Hospital
Gilead Sciences; Brigham and Women's Hospital

Completed

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

HIV Disease

United States
Technical University of Munich
Gilead Sciences; MUC Research GmbH

Completed

Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication

Insulin Resistance

Germany
Gilead Sciences

Completed

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States
Duke University

Completed

Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet (PHI04)

HIV

United States
Fundacion SEIMC-GESIDA
Merck Sharp & Dohme LLC

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression (GENIS)

HIV Infections | Severe Immunosuppression

Spain
Gilead Sciences

Completed

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

HIV-1 Infection

Spain, France, United States, Germany, Italy
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States, United Kingdom, France, Spain, Germany, Belgium, Puerto Rico, Canada, Italy, Austria, Australia, Portugal
Gilead Sciences

Completed

Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Thailand, South Africa
University of Washington
Gilead Sciences; Clinique des Maladies Infectieuses Ibrahima DIOP Mar/CRCF,...

Completed

An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal (Stribild HIV-2)

HIV-2 Infection

Senegal
Groupe d'Etude sur le Risque d'Exposition des Soignants...
Gilead Sciences

Completed

Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

HIV Risk

France
St Stephens Aids Trust
Merck Sharp & Dohme LLC

Completed

Renal Integrase Study

HIV

United Kingdom
Fred Hutchinson Cancer Center
National Institute on Drug Abuse (NIDA); Asociación Civil Impacta Salud y Educación... and other collaborators

Completed

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (SABES?)

HIV

Peru
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States, Puerto Rico
Henry M. Jackson Foundation for the Advancement...
Gilead Sciences

Withdrawn

Antiretroviral Therapy for Acute HIV Infection

HIV Infections

Uganda
Gilead Sciences

Completed

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

HIV

United States, South Africa
Gilead Sciences

Completed

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

HIV | HBV

United States, Canada, Japan
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

Canada, Switzerland, United States, France, Spain, Germany, Belgium, Austria, Italy, United Kingdom, Puerto Rico, Portugal
Gilead Sciences

Completed

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

HIV Infections | HIV

United States, Netherlands, Spain, Mexico, France, Thailand, Australia, United Kingdom, Dominican Republic
Janssen Sciences Ireland UC

Completed

Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination

Healthy

Belgium
Fundacion Clinic per a la Recerca Biomédica

Completed

Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open. (STRIB-PEP)

HIV

Spain
Gilead Sciences

Active, not recruiting

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

HIV Infections | Acquired Immune Deficiency Syndrome (AIDS)

United States, Thailand, Uganda, South Africa, Zimbabwe
Gilead Sciences

Completed

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

HIV Infections | Acquired Immunodeficiency Syndrome | HIV-1

United States, Canada
National Institute of Allergy and Infectious Diseases...
Microbicide Trials Network

Completed

Bone Mineral Density Substudy - An Ancillary Study to MTN-003

HIV Infections

Zimbabwe, Uganda
Saskatchewan Health Authority - Regina Area
Gilead Sciences

Unknown

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

Hepatitis C, Chronic | HIV/AIDS | Bone Diseases, Metabolic | Opioid Dependence | HIV-1-infection | HCV Coinfection | Buprenorphine Dependence | Methadone Dependence | Co-infection

Canada
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

HIV-1 Infection

United States, France, Austria, Germany
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Microbicide Trials Network

Completed

Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women

HIV Infections

South Africa, Uganda, Zimbabwe
Bayer

Completed

Interaction With HIV Antiretroviral Agents

HIV-DDI

United States
Saint Michael's Medical Center

Completed

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

HIV Infection | Hepatitis C Infection

United States
University of Washington
Bill and Melinda Gates Foundation

Completed

Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples (Partners PrEP)

HIV Infections | HIV-1 Infections

Kenya, Uganda
CONRAD
Eastern Virginia Medical School; University of North Carolina; Agility Clinical...

Completed

Exploratory Pharmacodynamic Study of Tenofovir-Based Products

HIV

United States
University of KwaZulu
Medical Research Council, South Africa; Centre for the AIDS Programme of Research...

Completed

Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women (PrEP)

HIV-1-infection

South Africa
University of Manitoba
World Health Organization; DMSC; Ashodaya Samithi

Completed

Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India (PrEP-India)

HIV Infection

India
Advancing Clinical Therapeutics Globally for HIV...
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Early ART to Limit Infection and Establishment of Reservoir (EARLIER)

HIV-1 Infection

United States, Brazil, Malawi, Zimbabwe, Thailand, Peru
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States, United Kingdom, Sweden, France, Puerto Rico, Netherlands, Italy, Portugal, Canada, Mexico, Dominican Republic
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors

Dyslipidemia | HIV

Spain
Technical University of Munich

Completed

Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication (TAF-IR)

Insulin Resistance

Germany
Merck Sharp & Dohme LLC

Active, not recruiting

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) (Impower-022)

Prophylaxis | Human Immunodeficiency Virus Type 1 | HIV-I

United States, South Africa, Uganda
Janssen Sciences Ireland UC

Completed

A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants

Healthy

Netherlands
Kirby Institute

Completed

PrEP Demonstration Project (PRELUDE Study) (PRELUDE)

HIV

Australia
Henry Ford Health System
Merck Sharp & Dohme LLC

Completed

Post-Exposure Prophylaxis in Health Care Workers (PEP)

Human Immunodeficiency Virus

United States

3

Subscribe